Trial Profile
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Ixazomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 26 May 2023 Planned End Date changed from 18 May 2023 to 18 May 2025.
- 26 May 2023 Planned primary completion date changed from 18 May 2023 to 18 May 2025.
- 26 May 2023 Status changed from recruiting to active, no longer recruiting.